๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Phase I Trial of Carboplatin, Paclitaxel, Etoposide, and Cyclophosphamide with Granulocyte Colony Stimulating Factor as First-Line Therapy for Patients with Advanced Epithelial Ovarian Cancer

โœ Scribed by Nadine Tung; Ross Berkowitz; Ursula Matulonis; Marc Quartulli; Michael Seiden; Young Kim; Jonathan Niloff; Stephen A. Cannistra

Book ID
112248088
Publisher
Elsevier Science
Year
2000
Tongue
English
Weight
56 KB
Volume
77
Category
Article
ISSN
0090-8258

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Phase I trial of paclitaxel, carboplatin
Phase I trial of paclitaxel, carboplatin, and topotecan with or without filgrastim (granulocyte-colony stimulating factor) in the treatment of patients with advanced, refractory cancer
โœ John D. Hainsworth; Howard A. Burris III; Lisa H. Morrissey; F. Anthony Greco ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 72 KB ๐Ÿ‘ 3 views

## Background: Topotecan is a new antineoplastic agent with a broad spectrum of activity. the purpose of this phase i trial was to define the maximum tolerated dose of topotecan when added to the widely used combination of paclitaxel and carboplatin. ## Methods: Patients with advanced cancer that

A Phase I trial of intravenous melphalan
A Phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma
โœ David M. Gershenson; Mitchell Morris; Thomas W. Burke; Charles Levenback; Judith ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 96 KB ๐Ÿ‘ 2 views

The primary purpose of this study was to establish the maximum tolerated dose (MTD) of intravenous melphalan in combination with paclitaxel and cisplatin plus granulocyte-colony stimulating factor (G-CSF) in patients with suboptimal advanced epithelial ovarian carcinoma or primary peritoneal carcino